Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Eltrombopag for Post Transplant Thrombocytopenia

This study is ongoing, but not recruiting participants.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: October 20, 2009
Last updated: April 20, 2017
Last verified: April 2017
The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.

Condition Intervention Phase
Drug: Eltrombopag
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: Eltrombopag for Post Transplant Thrombocytopenia

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Number of Participants with Platelet Count >/= 50 X 10^9/l at day 57 without platelet transfusion [ Time Frame: Baseline to Day 57 ]
    Development of a platelet count >/= 30 X 10^9/l at day 57 without platelet transfusion within 7 days, and participants who drop out of the trial before completion of day 57 with a platelet count >/= 30 X 10^9/l at the time of discontinuation are considered successes with respect to outcome (primary endpoint).

Estimated Enrollment: 64
Actual Study Start Date: February 2010
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eltrombopag
Starting dose 50 mg/day orally for 8 weeks
Drug: Eltrombopag
Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
Other Name: Promacta
Placebo Comparator: Placebo
Once a day orally for 8 weeks
Drug: Placebo
Once a day, orally for 8 weeks.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients >/= 35 days post HCT with Platelet count </= 20 x 10^9/l sustained for 7 days or patients are platelet transfusion dependent, and
  2. Neutrophil count >/= 1.5 x 10^9/l anytime within the last seven days before enrollment. Patients can be on myeloid or erythroid growth factors for example filgrastim), and
  3. Age >/= 18

Exclusion Criteria:

  1. Recurrence or progression of primary malignancy after HCT
  2. ALT >/= 2.5 times the ULN
  3. Serum bilirubin >2mg/dl (unless due to Gilbert's syndrome)
  4. Documented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the study.
  5. ECOG Performance status >2
  6. Pregnancy: Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. A woman of child-bearing potential is defined as a woman who has not been naturally post-menopausal for at least 12 consecutive months or with no previous surgical sterilization. A negative pregnancy test result will be required before any study drug is given.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01000051

United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Novartis Pharmaceuticals
Study Chair: Uday Popat, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01000051     History of Changes
Other Study ID Numbers: 2009-0106
NCI-2011-01099 ( Registry Identifier: NCI CTRP )
Study First Received: October 20, 2009
Last Updated: April 20, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by M.D. Anderson Cancer Center:
Transplant Thrombocytopenia
Hematopoietic cell transplantation
Low platelet count
Blood clot
Stem Cell Transplant
Blood And Marrow Transplantation

Additional relevant MeSH terms:
Blood Platelet Disorders
Hematologic Diseases processed this record on April 25, 2017